EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Outcomes in Patients With von Willebrand Disease Receiving Recombinant von Willebrand Factor on Demand and in Surgical Settings: Chart Review

Shawn X Sun iD, Shannely Lowndes iD, Rosa Willock, Cheryl Jones, Sarah Brighton iD

Clinical and Applied Thrombosis/Hemostasis · 2023

DOI: 10.1177/10760296231177294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2023. Verfasst von Shawn X Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc., Cambridge, MA, USA. Hauptthemen laut MEDLINE: von Willebrand Factor, von Willebrand Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Baxalta US Inc., a Takeda company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This European observational chart review assessed the efficacy/safety of recombinant von Willebrand factor (rVWF) for on-demand treatment of spontaneous/traumatic bleeds and prevention and/or treatment of surgery-related bleeding in adults with von Willebrand disease (VWD). Patients (n = 91) were enrolled at first rVWF administration (index). Data were collected for the 12 months before index and until death, loss to follow-up, or end of study (3-12 months after index). Fifteen patients reported an rVWF-treated spontaneous/traumatic bleed at index. Bleed resolution was obtained for 14 patients (unknown status, n = 1), and investigators assessed treatment satisfaction for 13 rVWF prescriptions (2 moderate, 5 good, and 6 excellent). rVWF was used to prevent/treat surgery-related bleeds at index in 76 patients. Bleed resolution was achieved in 25/58 rVWF-treated surgeries; bleed resolution was not applicable for 33 surgeries. In both groups, there were no reports of treatment-emergent adverse events after initiating rVWF, including hypersensitivity reactions, thrombotic events, and VWF inhibitor development. rVWF was shown to be effective for the on-demand treatment of spontaneous/traumatic bleeds, and for the prevention and treatment of surgical bleeds in this real-world VWD population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand Factorvon Willebrand DiseasesAdultHumansRecombinant ProteinsBlood Loss, Surgical

Stichwörter der Autor:innen

bleedingchart reviewon demandrecombinant von Willebrand factorsurgeryvon Willebrand disease

Substanzen

von Willebrand FactorRecombinant Proteins

Autor:innen und Institutionen

  • Takeda Development Center Americas, Inc., Cambridge, MA, USA.
  • Takeda Pharmaceuticals International AG, Zurich, Switzerland.
  • HCD Economics, Daresbury, UK.

ORCID-Profile: Shawn X Sun, Shannely Lowndes, Sarah Brighton

Förderung

  • Baxalta US Inc., a Takeda company

Zitieren

APA

Sun, S. X., Lowndes, S., Willock, R., Jones, C., & Brighton, S. (2023). Outcomes in Patients With von Willebrand Disease Receiving Recombinant von Willebrand Factor on Demand and in Surgical Settings: Chart Review. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296231177294

Vancouver

Sun SX, Lowndes S, Willock R, Jones C, Brighton S. Outcomes in Patients With von Willebrand Disease Receiving Recombinant von Willebrand Factor on Demand and in Surgical Settings: Chart Review. Clinical and Applied Thrombosis/Hemostasis. 2023. doi:10.1177/10760296231177294

BibTeX
@article{Sun2023,
  author = {Sun, Shawn X and Lowndes, Shannely and Willock, Rosa and Jones, Cheryl and Brighton, Sarah},
  title = {Outcomes in Patients With von Willebrand Disease Receiving Recombinant von Willebrand Factor on Demand and in Surgical Settings: Chart Review},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2023},
  doi = {10.1177/10760296231177294}
}
Kostenlos starten →